行情

CLBS

CLBS

Caladrius
NASDAQ

实时行情|Nasdaq Last Sale

2.300
+0.140
+6.48%
盘后: 2.290 -0.01 -0.43% 17:52 11/11 EST
开盘
2.160
昨收
2.160
最高
2.300
最低
2.110
成交量
1.12万
成交额
--
52周最高
5.44
52周最低
2.000
市值
2,394.53万
市盈率(TTM)
-1.3056
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLBS 新闻

  • 沪指高开震荡 金价连续多日走低
  • 新浪财经.6分钟前
  • 腾讯音乐高管解读财报:付费会员营收增速超内容成本
  • 新浪科技.4小时前
  • 伊朗石油部长:新油田让伊朗原油储量仅增222亿桶
  • 中国新闻网.4小时前
  • 沙特授予首批外国人永久居留权 150万一位
  • 新浪财经.4小时前

更多

所属板块

生物技术和医学研究
-0.40%
制药与医学研究
-0.41%

热门股票

名称
价格
涨跌幅

CLBS 简况

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
展开

Webull提供Caladrius Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。